Fathi et al. have explored the occurrence of differentiation syndrome in a cohort of 291 relapsed/refractory IDH2-mutant AML patients treated with enasidenib and observed a frequency of 11.7% [151]. Here, IDH2 is linked to acute myeloid leukemia.